Table 1 Clinical dose constraints for plan evaluations and initial optimization objectives for VMAT and IMPT plans
From: Assessment of IMPT versus VMAT plans using different uncertainty scenarios for prostate cancer
Structure | Dose | Volume constraint |
|---|---|---|
CTV | 95% DRX | ≥ 95% |
Max | ≤ 115% DRX | |
Anorectum | 4000 cGy | ≤ 35% |
6500 cGy | ≤ 17% | |
8000 cGy | ≤ 10% | |
Bladder | 4000 cGy | ≤ 50% |
6500 cGy | ≤ 25% | |
8000 cGy | ≤ 10% |